

Microsoft Bing

国内版国际版

HER2 targeted therapy in endometrial cancer: clinical and patholog

Sign in

ALLIMAGESVIDEOS

179,000 ResultsAny time

HER2 Testing in Endometrial Serous Carcinoma

<https://pubmed.ncbi.nlm.nih.gov/32649220>

This targeted therapeutic approach was recently endorsed by the National Comprehensive Cancer Network clinical guidelines. There is a growing interest among clinicians to obtain HER2 testing in endometrial serous carcinoma, and pathologists need to be prepared to recognize the unique characteristics of HER2 protein expression and gene amplification in these tumors and apply specific ...

Cited by: 3Author: Natalia Buza

Publish Year: 2020

HER2 Testing and Reporting in Endometrial Serous ...

<https://journals.lww.com/intjgynpathology/Abstract/...>

Abstract. Anti-HER2 therapy has recently emerged as an effective targeted treatment approach for patients with advanced stage and recurrent endometrial serous carcinoma, resulting in significantly prolonged progression-free and overall survival when combined with the standard chemotherapy regimen. Consequently, there is an increasing clinical demand in pathology laboratories for HER2

Search Tools

Turn off Hover Translation (关闭取词)

ALL IMAGES VIDEOS

13,900 Results Any time

[Human epidermal growth factor receptor-2 expression in ...](#)<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317932>

May 16, 2014 · The HER-2 (c-erbB-2) oncoprotein is a 185-kDa transmembrane cell surface receptor of the human epidermal growth factor family and usually expresses on epithelial cells. The tyrosine kinase activity of HER-2 intracellular domain triggers signal transduction that has important roles in cell proliferation, differentiation, and survival. As a ...

Cited by: 10

Author: Xiangjiao Meng, Renben Wang, Zhaoqin Hu...

Publish Year: 2014

[Significant intratumoral heterogeneity of human epidermal ...](#)<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832862>

Feb 19, 2016 · The assessment of human epidermal growth factor receptor 2 (HER 2) status is crucial for selecting patients with gastric cancer who may benefit from HER 2-targeted therapy. Accurate assessment using biopsy specimens is important for patients with advanced-stage cancer.

Cited by: 18

Author: Kazuki Kanayama, Hiroshi Imai, Misao Yon...

Publish Year: 2016

PEOPLE ALSO ASK

Are there any advances in HER2 targeted therapy?



Is the HER2 amplification a resistance marker for EGFR?



Are there any integrated genomic characterization of endometrial carcinomas?



Are there HER2 alterations across diverse tumor types?



Feedback

[Management of Early-Stage Human Epidermal Growth Factor ...](#)<https://ascopubs.org/doi/full/10.1200/OP.21.00020>

Jun 10, 2021 · The addition of trastuzumab to chemotherapy dramatically improved the prognosis of early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, 15%-31% of patients still develop disease recurrence, on the basis of long-term follow-up of adjuvant pivotal trials. A better understanding of tumor biology has led to the development of optimized anti-HER2 ...

Cited by: 1

Author: Sonia Pernas, Sara M Tolaney

Publish Year: 2021

28 Aug 2021, 10:07PM

2649 words • 11 matches • 9 sources

FAQ

iThenticate

64698_Auto_Edited-check.docx

Quoted Excluded

Bibliography Excluded

7%
5385.00

国内版

国际版

Human epidermal growth factor receptor 2 targeted therapy in en



ALL

IMAGES

VIDEOS

13,900 Results

Any time ▾

[Target Therapies for Uterine Carcinosarcomas: Current ...](#)

<https://pubmed.ncbi.nlm.nih.gov/28531111>

Based on our results, the differential expression and accessibility of epithelial cell adhesion molecule-1 on metastatic/chemotherapy-resistant CS cells in comparison to normal tissues and Human Epidermal Growth Factor Receptor 2 (HER2) open up new possibilities in the field of target therapy.

Cited by: 19

Author: Salvatore Giovanni Vitale, Antonio Simon...

Publish Year: 2017

[Human epidermal growth factor receptor-2 expression in ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317932>

May 16, 2014 · The HER-2 (c-erbB-2) oncoprotein is a 185-kDa transmembrane cell surface receptor of the human epidermal growth factor family and usually expresses on epithelial cells. The tyrosine kinase activity of HER-2 intracellular domain triggers signal transduction that has important roles in cell proliferation, differentiation, and survival. As a ...

Cited by: 10

Author: Xiangjiao Meng, Renben Wang, Zhaoqin ...

Publish Year: 2014

[Targeted Therapies in HER2-Positive Breast Cancer – a ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/26557822>

Jul 05, 2021 · The majority of the adenocarcinomas are hormone receptor (HR) positive and approximately 20% of the malignant breast tumors show an overexpression of human epidermal growth factor receptor 2 (HER2) on their cell surface . Identification of receptor expression offers treatment options for individualized targeted therapies.

Cited by: 23

Author: Amelie Schramm, Nikolaus De Gregorio, ...

Publish Year: 2015

[Significant intratumoral heterogeneity of human epidermal ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832862>

Feb 19, 2016 · The assessment of human epidermal growth factor receptor 2 (HER 2) status is crucial for selecting patients with gastric cancer who may benefit from HER 2-targeted therapy. Accurate assessment using biopsy specimens is important for patients with advanced-stage cancer.

Cited by: 18

Author: Kazuki Kanavama, Hiroshi Imai, Misao Y...